【US stock movement】Kestra Medical surged on October 15: guidance revision, performance growth, and wearable medical devices

Kestra Medical October 15 Significant Surge Interpretation

Keywords: Raised guidance, revenue growth, wearable medical

1. On September 14, 2026, the company announced first-quarter revenue for fiscal year 2027 of $31 million, a year-on-year increase of 60%; gross margin increased from 45.7% in the same period last year to 56.5%, and gross profit grew to $17.5 million.

2. On September 14, 2026, the company raised its fiscal year 2027 revenue guidance from $137 million to $141 million, expecting a year-on-year increase of 48%. Revenue growth stems from the expansion of the wearable cardioverter defibrillator market, increased market share, new sales regions, a higher proportion of in-network patients, and improvements in revenue cycle management.

3. On October 1, 2026, the company received a five-star rating as "America's Best Medium-Sized Companies 2026" from Newsweek and became the only company in the medical device manufacturing category to receive a five-star rating. The company specializes in wearable medical devices and digital healthcare, with its core product being the ASSURE wearable cardioverter defibrillation system.

(Disclaimer: This content is generated by AI technology based on publicly available information for summary purposes only. It is for reference and does not constitute investment advice.)